All In Biotech

Drug Trial Radar · NCT03700749

FALCON Trial Testing Measures to Reduce Surgical Site Infection

Pragmatic Multicentre FActorial Randomised Controlled triaL Testing Measures to reduCe Surgical Site Infection in lOw and Middle Income couNtries

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 5,788 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,788

Actual

Start

Nov 29, 2018

Primary completion

Sep 7, 2020

Study completion Oct 31, 2020

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lagos State University; Kigali University Teaching Hospital; Christian Medical College and Hospital, Ludhiana, India; University of Edinburgh; University of Witwatersrand, South Africa; Abomey Calavi; Hospital Espanol Veracruz; Ministry of Health, Ghana
First posted
Oct 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

FALCON is a Pragmatic multi-centre trial testing measures to reduce superficial or deep skin infection following abdominal surgery in low and middle income countries. The trial will recruit patients undergoing abdominal surgery. Recruited participants will be randomly assigned to four arms to receive different combinations of skin preparation and sutures for would closure: A. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and non-coated suture for wound closure; B. In this arm surgeon will use 2% alcoholic chlorhexidine for skin cleansing and triclosan coated suture for wound closure; C. In this arm surgeon will use for operation 10% aqueous povidone-iodine for skin cleansing and non-coated suture for wound closure; D. In this arm surgeon will use 10% aqueous povidone-iodine for skin cleansing and triclosan-coated suture.

Conditions

  • Abdominal Surgery
  • Surgical Site Infection

Interventions

  • 2% chlorhexidine + non-coated sutureDrug

    Interventions: 2% alcoholic chlorhexidine non-coated suture

  • 2% chlorhexidine + coated sutureDrug

    Interventions: 2% alcoholic chlorhexidine triclosan coated suture

  • 10%povidone-iodine + non-coated sutureDrug

    Interventions: 10% povidone-iodine non-coated suture non-coated suture

  • 10%povidone-iodine + coated sutureDrug

    Interventions: 10% povidone-iodine triclosan coated suture

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Surgical site infection (SSI)Time frame: At 30-days post-surgery

Locations

7 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Abomey Calavi

    Cotonou, Benin

  • Tamale Teaching Hospital, Tamale

    Tamale, Ghana

  • Christian Medical College and Hospital Ludhiana

    Ludhiana, India

  • Hospital Espanol Veracruz

    Veracruz, Mexico

  • Lagos University Teaching Hospital

    Lagos, Nigeria

  • University Teaching Hospital of Kigali (Hub), Kigali

    Kigali, Rwanda

  • University of the Witwatersrand

    Johannesburg, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.